Pin Therapeutics
October 18, 2023
Franciscan B
Oncology
Company Description: We are a biotech company that has been developing new drugs by focusing on the protein degrader field since 2016/2017. About 50 people are working together in Korea, the United States, and through the CRO (20 FTEs).
IPO plan: 2025 H1 (Korean stock market, Kosdaq)
Strong discovery platform capability:
- PinE3_Novel E3 Ligase ligand discovery capability
- Ligase2 Program_Novel E3 ligase ligand that potentially works with any target protein (mostly, focused on oncology)
- PinGLUE_Molecular Glue Degrader discovery capability
Programs:
- CK1a-Selective Molecular Glue Degrader (Preclinical) - Blood & Solid tumor
- Discovery program: 7 programs
Country
Korea, Republic of
Website
https://www.pintherapeutics.com/
CEO/Top Company Official
Hyunsun Jo
Lead Product in Development
Two own platform technologies.
One of lead pipeline is under pre-clinical strage.
Development Phase of Primary Product
Pre-Clinical
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)